Rockefeller Capital Management L.P. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 326,466 shares of the biopharmaceutical company’s stock after purchasing an additional 58,355 shares during the period. Rockefeller Capital Management L.P.’s holdings in Alnylam Pharmaceuticals were worth $28,573,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $137,000. Mutual of America Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 98.5% in the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after acquiring an additional 960 shares in the last quarter. IPG Investment Advisors LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $217,000. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Alnylam Pharmaceuticals by 600.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 1,953 shares in the last quarter. Finally, First Republic Investment Management Inc. bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $230,000. Institutional investors own 90.37% of the company’s stock.
ALNY stock opened at $88.16 on Tuesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $71.85 and a twelve month high of $153.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.22 and a current ratio of 13.22. The company has a market capitalization of $8.88 billion, a PE ratio of -16.27 and a beta of 2.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The company had revenue of $29.91 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter last year, the company earned ($1.07) earnings per share. The company’s revenue for the quarter was up 87.8% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.28 EPS for the current fiscal year.
Several research analysts have issued reports on the company. Cowen reiterated a “buy” rating and issued a $147.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 4th. JMP Securities set a $198.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 28th. Needham & Company LLC set a $152.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 27th. ValuEngine upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 28th. Finally, BidaskClub upgraded Alnylam Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, July 13th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $143.82.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the transaction, the chief operating officer now owns 1,916 shares in the company, valued at $229,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.70% of the stock is owned by company insiders.
WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/06/alnylam-pharmaceuticals-inc-alny-shares-bought-by-rockefeller-capital-management-l-p.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Article: Technical Analysis of Stocks and What It Means
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.